Astria Therapeutics Inc.

4 trials 2 recruiting Commercial sponsor

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

2 Recruiting

2 Completed trials

11 Countries active

2 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I/II

Phase III: 2 Phase II: 1 Phase I/II: 1

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Hereditary angioedema 4

Top IMPs

NAVENIBART 3 STAR-0215 1

All trials

4 total

A Long-term Study of Navenibart in Participants with Hereditary Angioedema Recruiting

2025-521142-22-00 Phase III 11 countries NAVENIBART
A study of Navenibart in Participants with Hereditary Angioedema Recruiting

2025-521660-35-00 Phase III 11 countries NAVENIBART
A Long-term trial to learn about a study drug (STAR-0215) in adults with hereditary angioedema Ended

2023-506540-16-01 Phase II 4 countries NAVENIBART
A trial to learn about a study drug (STAR-0215) in adults with hereditary angioedema Ended

2022-502953-32-01 Phase I/II 4 countries STAR-0215

Showing 1–4 of 4 trials

← All sponsors A–Z